Efficacy of vaccine NFU1 (S-) MRC5 given after an initial clinical episode in the prevention of herpes genitalis

Ciaran Woodman; Alexander Buchan; A Fuller; C Hartley; G R B Skinner; D Stocker; D Sugrue; JC Clay; G Wilkins; C Wiblin

doi:10.1136/sti.59.5.311

Efficacy of vaccine NFU1 (S-) MRC5 given after an initial clinical episode in the prevention of herpes genitalis

Ciaran Woodman, Alexander Buchan, A Fuller, C Hartley, G R B Skinner, D Stocker, D Sugrue, JC Clay, G Wilkins, C Wiblin

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

A subunit antigenoid vaccine, Ac NFU1 (S-) MRC 5, was used in patients who had had a clinical episode of herpes genitalis. The rate of recurrence was compared with that in unvaccinated patients to determine the efficacy of vaccination in preventing recurrence and spread of the virus in the community. Seven of 22 (31%) vaccinated patients had eight recurrences after the initial clinical episode; in contrast there were 51 recurrences in 17 of 20 (85%) unvaccinated patients. Although further studies are needed, the results indicate that the vaccine may prevent recurrent episodes of herpes genitalis and thereby reduce the dissemination of this virus in the population.

Original language	English
Pages (from-to)	311-313
Number of pages	3
Journal	British Journal of Venereal Diseases
Volume	59
Issue number	5
DOIs	https://doi.org/10.1136/sti.59.5.311
Publication status	Published - 1 Oct 1983

Keywords

vaccine
NFU1(S) MRC5
prevention
herpes
genitalis

ASJC Scopus subject areas

Medicine(all)
Health Professions(all)
Immunology and Microbiology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/sti.59.5.311

Cite this

@article{590c5e5955bb440093f80b699ffddc6b,

title = "Efficacy of vaccine NFU1 (S-) MRC5 given after an initial clinical episode in the prevention of herpes genitalis",

abstract = "A subunit antigenoid vaccine, Ac NFU1 (S-) MRC 5, was used in patients who had had a clinical episode of herpes genitalis. The rate of recurrence was compared with that in unvaccinated patients to determine the efficacy of vaccination in preventing recurrence and spread of the virus in the community. Seven of 22 (31%) vaccinated patients had eight recurrences after the initial clinical episode; in contrast there were 51 recurrences in 17 of 20 (85%) unvaccinated patients. Although further studies are needed, the results indicate that the vaccine may prevent recurrent episodes of herpes genitalis and thereby reduce the dissemination of this virus in the population.",

keywords = "vaccine, NFU1(S) MRC5, prevention, herpes, genitalis",

author = "Ciaran Woodman and Alexander Buchan and A Fuller and C Hartley and Skinner, {G R B} and D Stocker and D Sugrue and JC Clay and G Wilkins and C Wiblin",

year = "1983",

month = oct,

day = "1",

doi = "10.1136/sti.59.5.311",

language = "English",

volume = "59",

pages = "311--313",

journal = "British Journal of Venereal Diseases",

issn = "0007-134X",

publisher = "British Medical Association",

number = "5",

}

TY - JOUR

T1 - Efficacy of vaccine NFU1 (S-) MRC5 given after an initial clinical episode in the prevention of herpes genitalis

AU - Woodman, Ciaran

AU - Buchan, Alexander

AU - Fuller, A

AU - Hartley, C

AU - Skinner, G R B

AU - Stocker, D

AU - Sugrue, D

AU - Clay, JC

AU - Wilkins, G

AU - Wiblin, C

PY - 1983/10/1

Y1 - 1983/10/1

N2 - A subunit antigenoid vaccine, Ac NFU1 (S-) MRC 5, was used in patients who had had a clinical episode of herpes genitalis. The rate of recurrence was compared with that in unvaccinated patients to determine the efficacy of vaccination in preventing recurrence and spread of the virus in the community. Seven of 22 (31%) vaccinated patients had eight recurrences after the initial clinical episode; in contrast there were 51 recurrences in 17 of 20 (85%) unvaccinated patients. Although further studies are needed, the results indicate that the vaccine may prevent recurrent episodes of herpes genitalis and thereby reduce the dissemination of this virus in the population.

AB - A subunit antigenoid vaccine, Ac NFU1 (S-) MRC 5, was used in patients who had had a clinical episode of herpes genitalis. The rate of recurrence was compared with that in unvaccinated patients to determine the efficacy of vaccination in preventing recurrence and spread of the virus in the community. Seven of 22 (31%) vaccinated patients had eight recurrences after the initial clinical episode; in contrast there were 51 recurrences in 17 of 20 (85%) unvaccinated patients. Although further studies are needed, the results indicate that the vaccine may prevent recurrent episodes of herpes genitalis and thereby reduce the dissemination of this virus in the population.

KW - vaccine

KW - NFU1(S) MRC5

KW - prevention

KW - herpes

KW - genitalis

U2 - 10.1136/sti.59.5.311

DO - 10.1136/sti.59.5.311

M3 - Article

SN - 0007-134X

VL - 59

SP - 311

EP - 313

JO - British Journal of Venereal Diseases

JF - British Journal of Venereal Diseases

IS - 5

ER -

Efficacy of vaccine NFU1 (S-) MRC5 given after an initial clinical episode in the prevention of herpes genitalis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this